U.S. Food and Drug Administration (FDA)
Is Liraglutide legal in United States?
Generics availableBrand Victoza and Saxenda plus several FDA-approved generics; liraglutide is still on FDA's shortage list and Saxenda is being discontinued
Approved generic versions are sold.
Liraglutide is FDA-approved as Victoza for type 2 diabetes (approved 2010) and as Saxenda for chronic weight management (approved 2014). Since December 2024 FDA has approved multiple generic liraglutide injections, including from Hikma, Lupin, Teva and others. FDA's shortage database still lists several liraglutide presentations as current shortages, and Novo Nordisk has notified FDA that Saxenda will be discontinued in January 2027. FDA's 1 May 2026 proposal not to list liraglutide on the 503B bulks list is open to comment; the shortage listing means compounding eligibility should be checked case by case.
Last verified 2026-09-29 · how we verify
Liraglutide elsewhere
Sources (5)
- 01VICTOZA (liraglutide) injection prescribing informationU.S. Food and Drug Administration · 2025-10 · accessed 2026-09-29
- 02SAXENDA (liraglutide) injection prescribing informationU.S. Food and Drug Administration · 2026-03 · accessed 2026-09-29
- 03Drugs@FDA data via openFDA: liraglutide applications (brands and generics)U.S. Food and Drug Administration · 2026-09-24 · accessed 2026-09-29
- 04FDA Drug Shortages data via openFDA: liraglutide injectionU.S. Food and Drug Administration · 2026-09-22 · accessed 2026-09-29
- 05List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposal not to include semaglutide, tirzepatide, liraglutide)Federal Register (FDA) · 2026-05-01 · accessed 2026-09-29